Motiv8 Investments’s Novo Nordisk NVO Stock Holding History

Motiv8 Investments’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$3	Buy	+61	New	+$3.12K	﹤0.01%	685

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Motiv8 Investments's NVO Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Novo Nordisk (NVO) in Q4 2025: 61 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #685 among its holdings.

1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

Motiv8 Investments held 61 shares of Novo Nordisk worth $3 as of Q4 2025.
Novo Nordisk was a new Motiv8 Investments position in Q4 2025.
Novo Nordisk made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #685 holding.
1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.